6th Antifibrotic Drug Development Summit
As the only industry-led forum providing biopharma with the insights necessary to make strategic and scientific decisions on their fibrosis pipeline, the 6th Antifibrotic Drug Development Summit returns to host the unmissable conversations transforming antifibrotic drug development research.
Explore fibroblast heterogeneity and macrophage biology, delve into repair and regeneration, and regulatory considerations and lessons learned from the clinical setbacks so far to supercharge your antifibrotic research and
drug development pipeline with leading experts from Boehringer Ingelheim, Genentech, Gilead, Novartis, Pfizer, Alentis, BiOrion and many more, don’t miss out on your unique opportunity to cross-fertilize fibrosis understandings and harness the transferable insights you need to transform your antifibrotic therapeutics.
Across 3 days of valuable content, unite with over 150 biotech and pharma to takeaway the critical insights across NASH, IPF, CKD, Scleroderma, renal, cardiac, and more to translate preclinical efficacy into clinical antifibrotic success. From tuning into repair and regeneration to exploring cellular mechanisms to identify a common fibrotic pathway, and navigating clinical trial design across fibrotic diseases, this is a conversation not to miss.